

# Photosensitizers in dentistry

**Authors**\_Dr D. Koteeswaran, Dr C. Pravda and Dr Ekta Ingle, India

**\_Photodynamic therapy (PDT)**, also known as photoradiation therapy, phototherapy, or photochemotherapy, involves the use of a photoactive dye (photosensitizer) that is activated by exposure to light of a specific wavelength in the presence of oxygen (Konopka et al.). The transfer of energy from the activated photosensitizer to available oxygen results in the formation of toxic oxygen species, such as singlet oxygen and free radicals. These very reactive chemical species can damage proteins, lipids, nucleic acids, and other cellular components. Depending on the type of agent, photosensitizers may be injected intravenously, ingested orally, or applied topically.

Although a number of different photosensitizing compounds such as methylene blue, rose bengal, and acridine are known to be efficient singlet oxygen generators (and therefore potential photodynamic therapy agents), a large number of photosensitizers are cyclic tetrapyrroles or structural derivatives of this chromophore; in particular porphyrin, chlorin, bacteriochlorin, expanded porphyrin, and phthalocyanine (PC's) derivatives.

This is possibly because cyclic tetrapyrrolic derivatives have an inherent similarity to the naturally occurring porphyrins present in living matter con-

sequently they have little or no toxicity in the absence of light (Leanne et al.).

Photosensitizers can be categorized by their chemical structures and origins. In general, they can be divided into three broad families:

- \_Porphyrin-based photosensitizer (e.g., Photofrin, ALA/PpIX, BPD-MA),
- \_Chlorophyllbased photosensitizer (e.g., chlorins, purpurins, bacteriochlorins), and
- \_Dye (e.g., phthalocyanine, naphthalocyanine) (Zheng Huan et al.).
- \_Photosensitizer families (Allison et al.)

- \_Porphyrin platform
- \_HpD (hematoporphyrin derivative)
- \_HpD-based
- \_BPD (benzoporphyrin derivative)
- \_ALA (5-aminolevulinic acid)
- \_Texaphyrins

- \_Chlorophyll platform
- \_Chlorins
- \_Purpurins
- \_Bacteriochlorins

- \_Dyes
- \_Phtalocyanine
- \_Naphthalocyanine.

## **\_Generations of photosensitizers**

Most of the currently approved clinical photosensitizers belong to the porphyrin family. Traditionally, the porphyrins and those photosensitizers developed in the 1970s and early 1980s are called first generation photosensitizers (e.g., Photofrin). Photofrin® (di-



hematoporphyrin ether), available for 30 years in its commercial form, and hematoporphyrin derivatives (HPDs) are referred to as first-generation sensitizers. Photofrin® is the most extensively studied and clinically used photosensitizer.

Porphyrin derivatives or synthetics made since the late 1980s are called second generation photosensitizer (e.g., ALA). Second-generation photosensitizers include 5-aminolevulinic acid (ALA), benzoporphyrin derivative (BPD), lutetium texaphyrin, temoporfin (mTHPC), tinethyletiopurpurin (SnET2), and talaporfin sodium (LS11). Foscan® (mTHPC), the most potent second-generation photosensitizer, has been reported to be 100 times more active than Photofrin® in animal studies. These photosensitizers have a greater capability to generate singlet oxygen; however, they can cause significant pain during therapy, and, because of their high activity, even dim light (60 Watt bulb) can lead to severe skin photosensitivity (Dougherty et al.).

The third agent, ALA, is an intrinsic photosensitizer that is converted in situ to a photosensitizer, protoporphyrin IX. Topical ALA and its esters have been used to treat pre-cancer conditions, and basal and squamous cell carcinoma of the skin.

Third generation photosensitizers generally refer to the modifications such as biologic conjugates (e.g., antibody conjugate, liposome conjugate) and built-in photo quenching or bleaching capability. Third-generation photosensitizers include currently available drugs that are modified by targeting with monoclonal antibodies. These terms are still being used although not accepted unanimously and dividing photosensitizing drugs into such generations may be very confusing. In lot of cases, the claim that newer generation drugs are better than older ones is unjustified. The premature conclusions on novel or investigational photosensitizers may send a misleading message to researchers or clinicians by suggesting that the older drugs should be replaced by the newer ones or wrongly imply to patients that newer photosensitizing drugs are superior to older ones.

Currently, only four photosensitizers are commercially available: Photofrin, ALA, Visudyne™ (BPD; Verteporfin), and Foscan. The first three have been approved by the FDA, while all four are in use in Europe.

### \_ Indications for photosensitizers

- \_ ALA-based PDT for the treatment of oral pre-malignant lesions
- \_ as an adjunctive in treatment of chronic periodontitis and periimplantitis

- \_ for disinfection of root canals in endodontic therapy
- \_ treatment of early head and neck carcinomas
- \_ palliative treatment for refractory head and neck cancer
- \_ as an intra-operative adjuvant therapy, for recurrent head and neck cancer.

### \_ Bibliography

1. Ackroyd, Roger, Keltly, Clive, Brown, Nicola, Reed, Malcolm. History of photodetection and photodynamic therapy. Nov 2001.
2. Allman R, Cowburn P, Mason M. Effect of photodynamic therapy in combination with ionizing radiation on human squamous cell carcinoma cell lines of the head and neck. British Journal of Cancer 2000; 83(5): 655–661.
3. Amy Forman Taub. Photodynamic therapy: Other uses. Dermatol Clin 2007; 25: 101–109.
4. Hain-Ming Chen, Chin-Tin Chen, Hsiang Yang. Successful treatment of oral verrucous hyperplasia with topical 5-aminolevulinic acid-mediated photodynamic therapy. Oral Oncology 2004; 40: 630–637.
5. Hanna Gerber, Piotr, Kamil Jurszyszyn. Photodynamic therapy in the treatment of the oral leukoplakia – Preliminary report. Dent. Med. Probl 2004; 41 (2): 225–228.
6. Hsin-Ming Chen, Chuan-Hang Yu, Tsuimin Tsai. Topical 5-aminolevulinic acid-mediated photodynamic therapy for oral verrucous hyperplasia, oral leukoplakia and oral erythroleukoplakia. Photodiagnosis and Photodynamic Therapy 2007; 4: 44–52.
7. Konopka K, Goslinski T. Photodynamic therapy in dentistry. J Dent Res 2007; 86(8).
8. Leanne B. Josefsen and Ross W. Boyle. Photodynamic Therapy and the Development of Metal-Based Photosensitisers. Metal-Based Drugs Volume 2008, 24 pages.
9. Ron R Allison, Gordon H Downie, Rosa Cuenca, Xin-Hua, Carter JH Childs, Claudio H Sibata. Photosensitizers in clinical PDT. Photodiagnosis and Photodynamic Therapy 2004; 1: 27–42.
10. Zheng Huang. A review of progress in clinical photodynamic therapy. Technol Cancer Res Treat 2005; 4(3): 283–293.

\_contact

laser

**Dr D. Koteeswaran MDS, FICD**  
 Department of Oral Medicine and Radiology  
 Meenakshi Ammal Dental College  
 Alapakkam Main Road  
 Maduravoyal  
 Chennai 600095, India  
 Tel.: +91 9840145918  
 Fax: +91 44 23781631  
 E-mail: drdkoti@yahoo.com